Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
Abroad (travel likely)RecruitingPHASE1
Conditions
EBV · Epstein-Barr Virus Infection · Infectious Mononucleosis · Mono
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (Jessica Durkee-Shock, M.D.) · jessica.durkee-shock@nih.gov · 301-761-6539
Study leads
Jessica R Durkee-Shock, M.D.
Principal Investigator
National Institute of Allergy and Infectious Diseases (NIAID)